Relationship between infarct size and serum uric acid levels during the acute phase of stroke


Uric acid has gained considerable attention as a potential neuroprotective agent in stroke during the last decades, however, its role in the pathophysiology of ischemic stroke remains poorly understood. A serial evaluation of uric acid levels during the acute phase of stroke and its association with infarct size on magnetic resonance imaging is lacking.We present a cohort study of 31 patients with ischemic stroke who were not candidates for thrombolysis according to current criteria at the time. We performed daily measurements of serum uric acid and total antioxidant capacity of plasma during the first week after symptoms onset and 30 days after. Infarct size was determined in the acute phase by a DWI sequence and the final infarct size with a control MRI (FLAIR) at day 30.Uric acid significantly decreases between days 2 to 6 compared to day 1, after adjustment by sex, age and DWI at diagnosis, with a nadir value at 72h. A mixed model analysis showed a negative association between DWI at diagnosis and uric acid evolution during the first week after stroke. Moreover, multivariable linear regression of uric acid values during follow up on DWI volumes demonstrated that DWI volume at diagnosis is negatively associated with uric acid levels at day 3 and 4. There were no significant associations between total antioxidant capacity of plasma and DWI at diagnosis, or FLAIR at any point.Patients with larger infarcts exhibited a significant decrease in serum uric acid levels, accounting for a more prominent reactive oxygen species scavenging activity with subsequent consumption and decay of this antioxidant. The different kinetics of total antioxidant capacity of plasma and serum uric acid levels suggests a specific role of uric acid in the antioxidant response in ischemic stroke. Figures

Rodrigo Fernández-Gajardo,José Manuel Matamala,Rodrigo Gutiérrez,Prudencio Lozano,Ignacio A. Cortés-Fuentes,Camilo G. Sotomayor,Gonzalo Bustamante,Juan A. Pasten,Gabriel Vargas,Rodrigo Guerrero,Pablo Reyes,Gabriel Cavada,Walter Feuerhake ,Ramón Rodrigo


julio 11, 2019

DOI: 10.1371/journal.pone.0219402

Investigador BNI: Dr. José Manuel Matamala (MD, PhD)